Top Markets
Coin of the day
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
Kedudukan dalam Saham #7141
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Harga Saham
$40.39
Disegerakkan terakhir: 2023-08-18
Modal Pasaran
$1.70B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Chinook Therapeutics, Inc. (KDNY)

Kategori

Sejarah harga saham bagi Chinook Therapeutics, Inc. (KDNY)
Harga penutupan tertinggi: $40.34 pada 2023-08-01

Harga penutupan terendah: $177.63 pada 2015-04-01
Sejarah harga saham Chinook Therapeutics, Inc. dari 2015 hingga 2026
Prestasi harga saham tahunan
Tahun Prestasi
2023 63.66%
2022 55.54%
2021 0.37%
2020 175.05%
2019 -57.15%
2018 -67.16%
2017 -26.51%
2016 -62.61%
2015 0.00%
Harga saham bagi syarikat atau pesaing serupa
Syarikat Harga saham Perubahan 1thn% Negara
$548.36 39.87%
US
$1.06K 50.29%
NL
$121.53 -12.48%
AU
$140.81 475.44%
US
$764.47 7.63%
CH